FDA+ channel feed – Endpoints News

FDA+ channel feed

PS: Did anyone at Biogen ask the FDA to pull an aducanumab conscientious objector off their expert panel? ‘No comment’

5 years ago

The Endpoints News poll: Should the FDA panel back an approval for aducanumab, or should they send Biogen packing?

5 years ago

Orchard halts dosing of EMA-approved Strimvelis after patient develops leukemia

5 years ago

Biogen dodges a bullet in its controversial quest to gain an approval for their experimental Alzheimer’s drug aducanumab

5 years ago

PDUFA VII: FDA and industry set priorities in first round of negotiations

5 years ago

Novo Nordisk quietly nabs a rare 'breakthrough' status in NASH for its cash cow

5 years ago

Enhertu picks up another win for AstraZeneca and Daiichi Sankyo, joining the priority review lane for gastric cancer

5 years ago

Once rejected, Kala's dry eye drug now gains entry to a field where Novartis is grooming its own blockbuster

5 years ago

Ultragenyx slams the brakes on rare disease study after all 5 patients are hit with a serious setback

5 years ago

Pandemic travel restrictions force FDA to delay a BLA review — involving a site inspection in Korea

5 years ago

FDA gives AstraZeneca the thumbs-up to restart PhIII Covid-19 vaccine trials, and J&J is preparing to resume its study

5 years ago

In historic Covid-19 adcomm, vaccine experts debate a sea of questions — but offer no clear answers

5 years ago

FDA anoints Gilead's remdesivir as the Covid-19 treatment winner, handing down full approval — despite some deep skepticism

5 years ago

On morning of FDA Covid-19 adcomm, Moderna completes PhIII enrollment, putting them neck-and-neck with Pfizer

5 years ago

Little Zosano takes another beating as the FDA slaps down their application for a migraine patch

5 years ago

As FDA sets the stage for the first Covid-19 vaccine EUAs, some big players are asking for a tweak of the guidelines

5 years ago

Oncology research mid-pandemic: Challenges may bring durable innovation

5 years ago

Cara lines up a $440M deal for US rights to its late-stage drug for severe itch, with $150M cash on the table

5 years ago

European regulators spurn Agios' AML drug Tibsovo, unconvinced by the same thin PhI data that won over the FDA

5 years ago

FDA officials, experts discuss impact of Covid-19 on cell and gene therapies

5 years ago

With all eyes on their Covid-19 drug, Regeneron wins a landmark approval in Ebola

5 years ago

Months after achieving unicorn status, Orca steers into the fast lane with an RMAT designation for cell therapy candidate

5 years ago

Vaxart was served a grand jury subpoena in July over its controversial role in OWS-funded preclinical study

5 years ago

Riding a PhII success, a small French biotech lands a rare 'breakthrough' status in NASH

5 years ago

First page Previous page 121 122 123124125 126 127 Next page Last page